[EN] BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE<br/>[FR] BETA-CARBOLINES UTILES POUR TRAITER UNE MALADIE INFLAMMATOIRE
申请人:MILLENNIUM PHARM INC
公开号:WO2004092167A1
公开(公告)日:2004-10-28
This invention provides beta-carboline compounds of formula (I) wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2 mediated diseases such as inflammatory diseases and cancer.
Compounds of the formula I
are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IκB kinase is involved.
式I的化合物适用于生产用于预防和治疗在其过程中涉及IκB激酶活性增加的疾病的药物。
Substituted beta carbolines
申请人:——
公开号:US20020099068A1
公开(公告)日:2002-07-25
The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I,
1
which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&kgr;B kinase is involved.
[EN] SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY<br/>[FR] BETA-CARBOLINES SUBSTITUEES AYANT UNE ACTIVITE INHIBITRICE DE L'IKB-KINASE
申请人:AVENTIS PHARMA GMBH
公开号:WO2001068648A1
公开(公告)日:2001-09-20
Compounds of the formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IλB kinase is involved.
式(I)的化合物适用于生产用于预防和治疗在其过程中涉及IλB激酶活性增加的疾病的药物。
BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE
申请人:Hepperle Michael E.
公开号:US20100093713A1
公开(公告)日:2010-04-15
This invention provides beta-carboline compounds of formula
wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R
1
, R
2
and R
3
are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2-mediated diseases such as inflammatory diseases and cancer.